Switch to:
Also traded in: Germany

Latest Guru Trades with OTCPK:CBDS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2833
Compare:TSE:7523, HKSE:08082, OSTO:ATIC, OCSE:SFG, ASX:TNK, TSE:6039, ASX:NVL, TSE:2344, TSE:9731, HKSE:08358, TSE:4656, OHEL:FONDIA, ASX:SHJ, ASX:AHX, LSE:KEYS, TSE:3685, TSE:6186, TSE:4696, TSE:6537, HKSE:00922 » details
Traded in other countries:9C4.Germany,
Headquarter Location:USA
Cannabis Sativa Inc and its subsidiary are engaged in research, development and licensing of specialized natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems.

Cannabis Sativa Inc along with its subsidiaries engages in the development and licensing of natural cannabis products. Its product offering includes cannabis formulas, edibles, topicals, strains, recipes and delivery systems under the Go Deep, Go Deep EXTRA (GDX), Face Garden, Body Garden and Lip Garden line of products. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula.

Ratios

vs
industry
vs
history
PB Ratio 39.51
CBDS's PB Ratio is ranked lower than
95% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. CBDS: 39.51 )
Ranked among companies with meaningful PB Ratio only.
CBDS' s PB Ratio Range Over the Past 10 Years
Min: 8.62  Med: 29.19 Max: 750
Current: 39.51
8.62
750
PS Ratio 140.34
CBDS's PS Ratio is ranked lower than
96% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. CBDS: 140.34 )
Ranked among companies with meaningful PS Ratio only.
CBDS' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 52.56 Max: 7790
Current: 140.34
1.76
7790
EV-to-EBIT -15.36
CBDS's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. CBDS: -15.36 )
Ranked among companies with meaningful EV-to-EBIT only.
CBDS' s EV-to-EBIT Range Over the Past 10 Years
Min: -116.7  Med: -16.3 Max: -0.1
Current: -15.36
-116.7
-0.1
EV-to-EBITDA -17.27
CBDS's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. CBDS: -17.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBDS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -994  Med: -14.05 Max: 280
Current: -17.27
-994
280
EV-to-Revenue 149.41
CBDS's EV-to-Revenue is ranked lower than
95% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. CBDS: 149.41 )
Ranked among companies with meaningful EV-to-Revenue only.
CBDS' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 151.25 Max: 4762.8
Current: 149.41
1.9
4762.8
Current Ratio 0.13
CBDS's Current Ratio is ranked lower than
96% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. CBDS: 0.13 )
Ranked among companies with meaningful Current Ratio only.
CBDS' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.32 Max: 6.75
Current: 0.13
0.04
6.75
Quick Ratio 0.12
CBDS's Quick Ratio is ranked lower than
94% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. CBDS: 0.12 )
Ranked among companies with meaningful Quick Ratio only.
CBDS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.3 Max: 6.68
Current: 0.12
0.03
6.68
Days Inventory 13.43
CBDS's Days Inventory is ranked higher than
94% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. CBDS: 13.43 )
Ranked among companies with meaningful Days Inventory only.
CBDS' s Days Inventory Range Over the Past 10 Years
Min: 13.43  Med: 21.33 Max: 2007.5
Current: 13.43
13.43
2007.5
Days Sales Outstanding 3.03
CBDS's Days Sales Outstanding is ranked higher than
99% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. CBDS: 3.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBDS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.03  Med: 21.18 Max: 37.76
Current: 3.03
3.03
37.76
Days Payable 141.62
CBDS's Days Payable is ranked higher than
85% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. CBDS: 141.62 )
Ranked among companies with meaningful Days Payable only.
CBDS' s Days Payable Range Over the Past 10 Years
Min: 78.21  Med: 234.64 Max: 88147.5
Current: 141.62
78.21
88147.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.20
CBDS's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. CBDS: -11.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBDS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -135.5  Med: -33.6 Max: 0
Current: -11.2
-135.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 2.67
CBDS's Price-to-Median-PS-Value is ranked lower than
92% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. CBDS: 2.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBDS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.21 Max: 118.4
Current: 2.67
0.1
118.4
Earnings Yield (Greenblatt) % -6.51
CBDS's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. CBDS: -6.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBDS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1185.7  Med: -6.1 Max: -0.9
Current: -6.51
-1185.7
-0.9

More Statistics

Revenue (TTM) (Mil) $0.60
EPS (TTM) $ -0.24
Beta10.85
Volatility98.70%
52-Week Range $1.92 - 9.74
Shares Outstanding (Mil)21.73

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK